平安好医生：快速拓客带动企业健管业务增长-20260327

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company's revenue for 2H25 reached 2.97 billion RMB, a year-on-year increase of 9.3%, surpassing the Visible Alpha consensus estimate of 2.94 billion RMB, primarily driven by rapid growth in corporate health management business due to group synergy [1] - Non-IFRS net profit was 250 million RMB, exceeding the consensus estimate of 160 million RMB, with a corresponding non-IFRS net profit margin of 8.4%, up 5.9 percentage points year-on-year, attributed to the increased proportion of high-margin corporate health management business, AI-enabled cost reduction and efficiency improvement, enhanced supply chain procurement capabilities, and some non-operating income [1] - The company is expected to benefit from deeper business collaboration post-consolidation with the group, opportunities in the commercial insurance sector, and ongoing AI technology implementation to enhance cost efficiency [1] Business Performance - The corporate health management revenue grew by 40.6% year-on-year to 1.31 billion RMB, driven by a steady increase in the number of partner enterprises [2] - The company reported a total of approximately 35 million paying users in 2025, an increase of 11.4%, achieving a penetration rate of 14% among the 250 million individual financial users of the Ping An Group [2] - The number of paying service enterprises reached 6,700, reflecting an increase of 83.1%, indicating robust customer acquisition progress [2] AI Development - The company has made significant progress in AI applications in healthcare, with AI contributing nearly 80 million RMB in gross profit, accounting for 4.5% of total gross profit [3] - The cost per consultation decreased by approximately 45% year-on-year in Q4 2025, thanks to the development of a comprehensive AI diagnosis and treatment system [3] - The management plans to increase investment in AI applications, transitioning from simple automation to deep assistance in various medical scenarios [3] Profit Forecast and Valuation - The non-IFRS net profit forecasts for 2026 and 2027 have been adjusted upward by 8.0% and 10.8% to 480 million RMB and 610 million RMB, respectively, due to the increasing share of platform business model and ongoing AI technology applications [4] - The valuation method has shifted from PS to EV/adjusted net profit, assigning a target EV/adjusted net profit multiple of 40x for 2026, reflecting a premium over the average of comparable companies [4] - The target price is set at 15.9 HKD per share, down from a previous estimate of 17.2 HKD, based on the new valuation approach [4]